Zobrazeno 1 - 10
of 81
pro vyhledávání: '"NAOTAKA NISHIYAMA"'
Autor:
Shinichi Sakamoto, Kodai Sato, Takahiro Kimura, Yoshiyuki Matsui, Yusuke Shiraishi, Kohei Hashimoto, Hideaki Miyake, Shintaro Narita, Jun Miki, Ryuji Matsumoto, Takuma Kato, Toshihiro Saito, Ryotaro Tomida, Masaki Shiota, Akira Joraku, Naoki Terada, Shigetaka Suekane, Tomoyuki Kaneko, Shuichi Tatarano, Yuko Yoshio, Takayuki Yoshino, Naotaka Nishiyama, Eiryo Kawakami, Tomohiko Ichikawa, Hiroshi Kitamura
Publikováno v:
Scientific Reports, Vol 14, Iss 1, Pp 1-11 (2024)
Abstract A multicenter study of nonmetastatic castration-resistant prostate cancer (nmCRPC) was conducted to identify the optimal cut-off value of prostate-specific antigen (PSA) doubling time (PSADT) that correlated with the prognosis in Japanese nm
Externí odkaz:
https://doaj.org/article/916b6526270845538ce6a993714a45e5
Autor:
Makito Miyake, Hiroshi Kitamura, Nobutaka Nishimura, Tatsuki Miyamoto, Tomonori Nakahama, Tomomi Fujii, Hiroaki Matsumoto, Hideyasu Matsuyama, Masaya Yonemori, Hideki Enokida, Rikiya Taoka, Takashi Kobayashi, Takahiro Kojima, Yoshiyuki Matsui, Naotaka Nishiyama, Hiroyuki Nishiyama, Kiyohide Fujimoto, Nishinihon Uro‐oncology Extensive Collaboration group and the Japanese Urological Oncology Group
Publikováno v:
BJUI Compass, Vol 5, Iss 2, Pp 269-280 (2024)
Abstract Objective The objective of this study is to validate the predictive ability of the 2021 European Association of Urology (EAU) risk model compared to that of existing risk models, including the 2019 EAU model and risk scoring tables of the Eu
Externí odkaz:
https://doaj.org/article/9c82631e4e444a6c8093d7f9162013b7
Autor:
Katsuhiro Ito, Yuki Kita, Akira Yokomizo, Jun Miki, Yuko Yoshio, Hiroaki Matsumoto, Takehiko Segawa, Takashi Karashima, Naotaka Nishiyama, Kazuto Imai, Shigetaka Suekane, Seiji Nagasawa, Shin Higashi, Hiroyuki Nishiyama, Hiroshi Kitamura, Takashi Kobayashi
Publikováno v:
Cancer Medicine, Vol 12, Iss 3, Pp 2325-2332 (2023)
Abstract Pembrolizumab, an anti‐programmed death 1 monoclonal antibody, has revolutionized the treatment of metastatic urothelial carcinoma. However, the optimal treatment duration for treatment responders has not been established. To address this,
Externí odkaz:
https://doaj.org/article/8233fb43169641d5938784ae9c87acbf
Autor:
Kazuyuki Numakura, Makito Miyake, Mizuki Kobayashi, Yumina Muto, Yuya Sekine, Nobutaka Nishimura, Kota Iida, Masanori Shiga, Shuichi Morizane, Takahiro Yoneyama, Yoshiaki Matsumura, Takashige Abe, Takeshi Yamada, Kazumasa Matsumoto, Junichi Inokuchi, Naotaka Nishiyama, Rikiya Taoka, Takashi Kobayashi, Takahiro Kojima, Hiroshi Kitamura, Hiroyuki Nishiyama, Kiyohide Fujimoto, Tomonori Habuchi
Publikováno v:
Cancers, Vol 15, Iss 7, p 2002 (2023)
Upper urinary tract urothelial carcinoma (UTUC) after intravesical bacillus Calmette-Guerin (BCG) therapy is rare, and its incidence, clinical impact, and risk factors are not fully understood. To elucidate the clinical implications of UTUC after int
Externí odkaz:
https://doaj.org/article/a45459f369e144ffa2473dab72c407af
Autor:
Kazuya Ishiguro, Hiroshi Kitajima, Takeshi Niinuma, Reo Maruyama, Naotaka Nishiyama, Hitoshi Ohtani, Gota Sudo, Mutsumi Toyota, Hajime Sasaki, Eiichiro Yamamoto, Masahiro Kai, Hiroshi Nakase, Hiromu Suzuki
Publikováno v:
Cell Death Discovery, Vol 7, Iss 1, Pp 1-13 (2021)
Abstract Epigenetic mechanisms such as histone modification play key roles in the pathogenesis of multiple myeloma (MM). We previously showed that EZH2, a histone H3 lysine 27 (H3K27) methyltransferase, and G9, a H3K9 methyltransferase, are potential
Externí odkaz:
https://doaj.org/article/56d3e7d185f340a8827e4ac800e9a4c1
Autor:
Kohei Hashimoto, Yasuhide Miyoshi, Tetsuya Shindo, Masakazu Hori, Yasumasa Tsuboi, Ko Kobayashi, Fumimasa Fukuta, Toshiaki Tanaka, Shintaro Miyamoto, Takeshi Maehana, Manabu Okada, Naotaka Nishiyama, Masahiro Yanase, Ryuichi Kato, Hiroshi Hotta, Yasuharu Kunishima, Atsushi Takahashi, Shiro Hinotsu, Koh‐ichi Sakata, Hiroshi Kitamura, Hiroji Uemura, Naoya Masumori
Publikováno v:
Cancer Medicine, Vol 9, Iss 22, Pp 8579-8588 (2020)
Abstract Background To best employ radium‐223 dichloride (Ra‐223) for patients with castration‐resistant prostate cancer (CRPC) and bone metastasis, we investigated the bone‐predominant status in patients treated with Ra‐223. Methods We ret
Externí odkaz:
https://doaj.org/article/2097f250a7eb442e825c4804a5c9ed56
Autor:
Naotaka Nishiyama, Megumi hirobe, Takuya Kikushima, Masahiro Matsuki, Atsushi Takahashi, Masahiro Yanase, Keisuke Ichimatsu, Masayuki Egawa, Norihiro Hayashi, Takahito Negishi, Naoya Masumori, Hiroshi Kitamura
Publikováno v:
BMC Urology, Vol 20, Iss 1, Pp 1-7 (2020)
Abstract Background The neutrophil-lymphocyte ratio (NLR) is a well-known prognostic marker in various cancers. However, its role as a predictive marker for the effectiveness of nivolumab in patients with metastatic RCC (mRCC) remains unclear. We eva
Externí odkaz:
https://doaj.org/article/021425dba2a043ae8d5d05b965a7d0bc
Autor:
Makito Miyake, Nobutaka Nishimura, Kota Iida, Tomomi Fujii, Ryoma Nishikawa, Shogo Teraoka, Atsushi Takenaka, Hiroshi Kikuchi, Takashige Abe, Nobuo Shinohara, Eijiro Okajima, Takuto Shimizu, Shunta Hori, Norihiko Tsuchiya, Takuya Owari, Yasukiyo Murakami, Rikiya Taoka, Takashi Kobayashi, Takahiro Kojima, Naotaka Nishiyama, Hiroshi Kitamura, Hiroyuki Nishiyama, Kiyohide Fujimoto
Publikováno v:
Cancers, Vol 13, Iss 11, p 2615 (2021)
The 2016 World Health Organization classification newly described infiltrating urothelial carcinoma (UC) with divergent differentiation (DD) or variant morphologies (VMs). Data comparing oncological outcomes after bladder-preservation therapy using i
Externí odkaz:
https://doaj.org/article/0ccc8ca90d1f464e9b6b93ecef56a143
Autor:
Takahito Negishi, Tohru Nakagawa, Naotaka Nishiyama, Hiroshi Kitamura, Eijiro Okajima, Nobuki Furubayashi, Yoshifumi Hori, Kentarou Kuroiwa, Yuhyon Son, Narihito Seki, Toshihisa Tomoda, Motonobu Nakamura
Publikováno v:
Japanese Journal of Clinical Oncology. 52:1430-1435
Introduction Metastases from renal cell carcinoma develop in various organs. However, the breadth of discrepancy in response to immune checkpoint inhibitors across tumor sites within the same individual remains unclear. Patients and methods We review
Autor:
Takamitsu Inoue, Makito Miyake, Nobutaka Nishimura, Mizuki Onozawa, Soki Kashima, Kazuyuki Numakura, Shintaro Narita, Kota Iida, Motohide Uemura, Yuto Matsushita, Junichi Inokuchi, Yoshiyuki Matsui, Rikiya Taoka, Takahiro Kojima, Takashi Kobayashi, Naotaka Nishiyama, Hiroshi Kitamura, Hiroyuki Nishiyama, Kiyohide Fujimoto, Tomonori Habuchi
Publikováno v:
Urology. 167:158-164
To compare the therapeutic effect of Bacille Calmette-Guérin (BCG) intravesical instillation in older and younger patients with high-risk non-muscle-invasive bladder cancer. The comparison was performed with propensity score matching (PSM) without t